This could mean that clinical boundaries between psychiatric disorders might not reflect their underlying biology, Brainstorm Consortium researchers said.
The company presented data demonstrating that ADHD patients with mutations in nine genes had a clinically meaningful and statistically significant response to AEVI-001.
NEW YORK (GenomeWeb) – Neuropsychiatric molecular diagnostics firm Assurex today said that it has secured a $25 million credit facility and $7 million in investments.
The funds will be used to increase clinical adoption of the Mason, Ohio-based firm's GeneSight products.
NEW YORK (GenomeWeb News) – The European Union has approved a project aimed at determining the causes of extreme aggressive behavior and is providing €6 million ($8 million) to the effort.
AssureRx Launches GeneSightRx ADHD
AssureRx Health this week launched a pharmacogenetic test, called GeneSightRx ADHD, for characterizing patients' response to a variety of attention deficit hyperactivity disorder drugs.
